Ares Credit funds served as the administrative agent on $300 million in incremental debt financing for Tempus AI, a technology company aiming to lead the adoption of AI to advance precision medicine and patient care. The financing is intended to support Tempus’ previously announced acquisition of Ambry Genetics, which closed on Feb. 3, 2025. Combined with $260 million of capital provided in 2022 and 2023, Ares Credit funds have provided Tempus a total debt package of approximately $560 million.
“We are pleased to upsize our investment in Tempus, underscoring Ares’ ability to provide flexible capital at scale to both non-sponsor-backed and sponsor-backed borrowers,” Douglas Dieter, partner in the Ares Credit Group., said “Over the last two years, we’ve been impressed by the Tempus team’s execution of its growth strategy and complementary acquisition of Ambry, and we look forward to further supporting their efforts in AI-enabled solutions that help advancements in medicine.”
“We appreciate this latest investment from Ares, which supports Tempus’ acquisition of Ambry and our commitment to deliver technological innovation that can help healthcare providers improve patient outcomes,” Jim Rogers, chief financial officer of Tempus, said.
